Targeting B-cell maturation antigen in multiple myeloma.

Abstract

Novel effective immunotherapies are needed for patients with multiple myeloma (MM), since disease recurrence remains a major obstacle. B-cell maturation antigen (BCMA), a cell surface protein universally expressed on malignant plasma cells , has emerged as a very selective antigen to be targeted in novel treatments for MM. We here first review BCMA-related biology, and then highlight the recent clinical development of a novel afucosylated anti-BCMA monoclonal antibody conjugated with monomethyl auristatin F via noncleavable linker (GSK2857916). Chimeric antigen receptor-expressing T cells targeting BCMA may also induce specific and durable anti-MM responses by patients' own effector cells. Clinical trials testing these two approaches (NCT02064387, NCT02215967) are currently ongoing in relapsed and refractory MM patients.

• Authors: Yu-Tzu Tai, Kenneth C Anderson
• Journal: Immunotherapy (Immunotherapy) Vol. 7 Issue 11 Pg. 1187-99 ( 2015) ISSN: 1750-7448 [Electronic] England
• PMID: 26370838 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Antibodies, Monoclonal
• Antigens, Neoplasm
• B-Cell Maturation Antigen
• Oligopeptides
• Receptors, Antigen, T-Cell
• Recombinant Fusion Proteins
• TNFRSF17 protein, human
• monomethylauristatin F

Topics

• Animals
• Antibodies, Monoclonal (chemistry, therapeutic use)
• Antigens, Neoplasm (immunology, metabolism)
• B-Cell Maturation Antigen (immunology, metabolism)
• Clinical Trials as Topic
• Humans
• Immunotherapy
• Molecular Targeted Therapy
• Multiple Myeloma (immunology, therapy)
• Oligopeptides (chemistry)
• Protein Engineering
• Receptors, Antigen, T-Cell (genetics)
• Recombinant Fusion Proteins (genetics)
• T-Lymphocytes (immunology, transplantation)